A clear mission and mandate

To represent the Quebec hemp and cannabis industry and contribute constructively and responsibly to its development. To establish itself as a key player in the Quebec hemp and cannabis ecosystem.  To be recognized by the members of the association as well as by industry stakeholders as a credible, constructive interlocutor with the ability to meet the strategic needs of the industry.

Our Members

A passionate cannabis community !
 

 The face of Quebec Hemp and Cannabis producers

 
Origine Nature
Logo de Origine Nature

At Origine Nature, our team understands the plant and its needs. Thanks to years of experience, passion and respect for everything we do, we have been able to grow cannabis that makes us proud.

Association Québécoise de l'Industrie du Cannabis

News

15,000 Denials at the SQDC Reignite the Debate on the Legal Age

15,000 Denials at the SQDC Reignite the Debate on the Legal Age

July 29 2026Daily news

More than 15,000 young people under the age of 21 were denied access to SQDC stores in one year. This figure raises a fundamental question: where do consumers aged 18 to 20 turn next? By excluding them from the legal market, Quebec is not preventing them from using cannabis. Rather, it is depriving them of access to regulated products—whose composition and THC content are clearly labeled—as well as to an environment governed by strict rules.

Health Canada Announces New Changes

Health Canada Announces New Changes

July 23 2026Canada

As part of its efforts to reduce administrative burden, Health Canada has created a repository to track changes made to its cannabis-related publications. The latest updates concern import permits, odour control and industrial hemp.

Dementia: Cannabis May Reduce Agitation in Patients

Dementia: Cannabis May Reduce Agitation in Patients

July 20 2026Research

A clinical study involving 120 people with advanced dementia suggests that an oral formulation combining THC and CBD may reduce agitation. After 12 weeks, nearly 90% of the participants who received the treatment showed an improvement in their symptoms, compared with about 23% in the placebo group.

Chargement en cours...